Dietrich J B, Ribéreau-Gayon G, Jung M L, Franz H, Beck J P, Anton R
Institut de Biologie Moléculaire et Cellulaire, Strasbourg, France.
Anticancer Drugs. 1992 Oct;3(5):507-11. doi: 10.1097/00001813-199210000-00010.
Mistletoe lectin (ML) I increases the production of cytokines by mononuclear cells and has been proposed as a useful biological response modifier in the treatment of cancer. Two other lectins, ML II and ML III, have been identified in mistletoe. We report that the N-terminal sequences of the three A chains of ML I, ML II and ML III are identical, and have interesting homology with the N-terminal sequences of the A chain of ricin-like toxins and of single-chain ribosome-inhibiting proteins. In addition, the three mistletoe lectins inhibit the growth of the human tumor cell line Molt 4, ML III being the most potent. followed by ML II and ML I. This inhibition is suppressed by addition of rabbit anti-ML I antibodies to the cultured cells. The data obtained suggest that the three lectins have amino acid sequences which show extensive homology and exert very similar biological effects. They may be derived from the same precursor.
槲寄生凝集素（ML）I可增加单核细胞产生细胞因子的量，并已被提议作为治疗癌症的一种有用的生物反应调节剂。在槲寄生中还鉴定出了另外两种凝集素，即ML II和ML III。我们报告称，ML I、ML II和ML III的三条A链的N端序列相同，并且与蓖麻毒素样毒素的A链以及单链核糖体抑制蛋白的N端序列具有有趣的同源性。此外，这三种槲寄生凝集素可抑制人肿瘤细胞系Molt 4的生长，其中ML III的作用最强，其次是ML II和ML I。向培养细胞中加入兔抗ML I抗体可抑制这种抑制作用。所获得的数据表明，这三种凝集素具有显示出广泛同源性的氨基酸序列，并发挥非常相似的生物学效应。它们可能源自同一前体。
